Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Arcutis posts results for roflumilast psoriasis extension trial, NCT04286607Sep 9Trial updateArcutis Biotherapeutics, Inc.roflumilast
Arcutis posts pediatric PK results for topical roflumilast in plaque psoriasisAug 7Trial updateArcutis Biotherapeutics, Inc.roflumilast
Arcutis posts Q2 2026 profit as ZORYVE sales climb, raises full-year guidanceAug 5Quarterly updateArcutis Biotherapeutics, Inc.roflumilast
Zhongmei Huadong registers Phase 3 roflumilast foam trial for seborrheic dermatitis with ArcutisJul 6Trial updateArcutis Biotherapeutics, Inc.roflumilast